title: Use of RENAL nephrometry scores for predicting tumor upgrading between core biopsies and surgical specimens: a prospective ex vivo study.
abstract: Determination of Fuhrman grade (FG) on biopsies of renal masses is relatively inaccurate, being prone to underestimating the true grade as ascertained from surgical specimens. This study evaluated whether anatomical features of tumors could predict tumor upgrading between core biopsies and surgical specimens. We prospectively enrolled 249 patients undergoing surgical resection of solid renal masses at our institution from 2012 to 2013. Tumor anatomical features were defined using RENAL nephrometry scores. Two peripheral and 1 central ex vivo core biopsies were taken from surgical specimens with an F18-gauge needle. Logistic regression was used to assess associations between covariates and FG upgrading. A comprehensive nomogram was constructed to quantitate the probability of tumor upgrading. The median tumor size was 4.75 cm and FG upgrading occurred in 43.6% of cases. In tumors of low, intermediate, and high complexity, the risk of FG upgrading was 22.0%, 47.6%, and 50.6%, respectively. According to multivariate analyses, anatomical features R (radius) and L (location) scores correlated significantly with FG upgrading. A combination of anatomical features and core biopsy findings predicted tumor upgrading with an accuracy of 0.884. With a threshold of 30%, our nomogram identified 92.4% of cases with upgrading; however, it overrated 26.8% of patients without upgrading. This ex vivo prospective study demonstrated that RENAL nephrometry score can aid prediction of FG upgrading between core biopsies and surgical specimens. Our nomogram uses anatomical features to predict true FG from renal biopsies.
authors.affiliation: From the Department of Urology (GMZ, YZ, HKW, GHS, HLZ, BD, DWY); Department of Pathology (HLG, CFW, Fudan University Shanghai Cancer Center; and Department of Oncology (GMZ, YZ, DWY), Shanghai Medical College, Fudan University, Shanghai, China.
authors.forename: Gui-Ming
authors.initials: GM
authors.lastname: Zhang
authors.forename: Yao
authors.initials: Y
authors.lastname: Zhu
authors.forename: Hua-Lei
authors.initials: HL
authors.lastname: Gan
authors.forename: Hong-Kai
authors.initials: HK
authors.lastname: Wang
authors.forename: Guo-Hai
authors.initials: GH
authors.lastname: Shi
authors.forename: Hai-Liang
authors.initials: HL
authors.lastname: Zhang
authors.forename: Bo
authors.initials: B
authors.lastname: Dai
authors.forename: Chao-Fu
authors.initials: CF
authors.lastname: Wang
authors.forename: Ding-Wei
authors.initials: DW
authors.lastname: Ye
mesh_terms: D001706:Biopsy; D002292:Carcinoma, Renal Cell / Q000473:pathology*; D005260:Female; D006801:Humans; D007668:Kidney / Q000473:pathology*; D007680:Kidney Neoplasms / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D011237:Predictive Value of Tests; D011446:Prospective Studies